Danaher Corporation’s Analyst Meeting Review

Danaher Corporation (NYSE:DHR) hosted an in-person analyst meeting last week, providing investors a deeper dive into its portfolio evolution, DBS success stories, and the company’s longer-term targets.

The company announced its plans to separate its leading Water Quality test/treatment business and Product ID non-contact printing business into a standalone entity by Q4/23.

Analysts at RBC Capital expect the company can over-deliver and orchestrate the separation earlier than the initial target. According to the analysts, the upside in Cepheid COVID testing revenues in Q3/22 was nice to see, and the new long-term targets look achievable to them, especially given underlying market growth in biologics and Danaher’s share gains.